Medical Devices – U.S. Regulatory Framework
The Food and Drug Administration (FDA) is the authority regulating Medical Devices in the U.S., to ensure their safety and effectiveness. Medical devices are divided into three classes (I, II and III) and this classification defines the regulatory requirements for each device type.

MEDICAL DEVICES LEGAL FRAMEWORK IN THE U.S.

All medical devices must comply with the General Controls of the Medical Device Amendments (1976) to the Food, Drug and Cosmetic Act (FD&C Act). General Controls provide the U.S. Food and Drug Administration (FDA) the methods for regulating devices. The FDA’s Center for Devices and Radiological Health (CDRH) is in charge of regulating companies who manufacture, repackage, relabel and/or import medical devices which are sold in the United States (U.S.).

In the General Controls are included provisions concerning: adulteration; misbranding; device registration and listing; premarket notification; banned devices; notification and repair, replacement and refund; records and reports; restricted devices and Good Manufacturing Practices (GMP).

Medical devices are divided in three risk classes (I, II and III). This means that the medical device classification will depend on risk to patient/user, intended use and indications for use. All three classes are subject to the General Controls provisions of the Amendments. Class I medical devices are not intended for use in supporting or sustaining life or to be of substantial importance in preventing impairment to human health. These medical devices may not present a potential unreasonable risk of illness or injury. According to the Amendments, Class I medical devices are the ones which pose the lowest risk.  Class III devices are those with the greatest risk and consequently are most regulated, being subjected to premarket approval (PMA).

For Class I and Class II devices, a 510(k) premarket must be submitted. This submission requires demonstration of a substantial equivalence to another legally marketed device in the U.S. A non-equivalent device must have an approved premarket approval (PMA) application or be reclassified into Class I or Class II before being marketed.

Some medical devices considered Class I and II are exempt from 510(k) requirements), but they must still comply with other requirements (regulatory controls) unless the device is explicitly exempt from those requirements as indicated in the regulation for that device type. A device may be exempt from 510(k) requirements if the FDA determines that a 510(k) is not required to provide reasonable assurance of safety and effectiveness for the device.

Establishments of medical devices manufacturers (and other specified processors) must be registered with the FDA. A list of all the devices manufactured in such establishments must also be provided. The same applies to importers, repackers and relabelers of medical devices.

The FDA may restrict the sale, distribution or use of a medical device if its safety and effectiveness cannot be assured.

INTRODUCING MEDICAL DEVICES IN THE U.S.

Classification of the medical device is the first step for its placement in the U.S. market. Secondly, the company needs to identify the correct premarket submission, which will depend on the medical device classification. For a Class I or Class II device (not exempt), a premarket submission (510(k)) needs to be submitted to FDA to demonstrate that the device is safe and effective, at least 90 days before introducing the device onto the market. It is not possible to commercially distribute the medical device until a letter of substantial equivalence from FDA authorizes it.

When it comes to Class III medical devices, it is mandatory a premarket approval application (PMA), unless there is a preamendments device (on the market prior to the passage of the medical device amendments in 1976, or substantially equivalent to such a device) and PMA’s have not been called for. A 510(k) premarket submission would be the way to go in that case. The PMA process is more complex and includes submission of clinical data to support claims made for the device. A fee must be paid both in 510(k) premarket submission and PMA application.

After documents submission and payment of correspondent fees, the FDA will review the submission and decide on the approval of the medical device, within 90-180 days. Class I and Class II device manufacturers are not inspected by the FDA before device registration. Nevertheless, the FDA may conduct random inspections after registration.

Finally, the medical device establishment must be registered in the FDA and the correspondent fees must be paid. The company and device registration status will be listed on the FDA website and the authorization granted will not expire as long as there are no changes made to the medical device (design, intended use, etc.)

References:

U.S. Food and Drug Administration (FDA) – Overview of Device Regulation – https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/overview-device-regulation

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »